Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of intercalated combination of doublet chemotherapy of paclitaxel plus carboplatin and erlotinib on patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation.
Epistemonikos ID: c6299128b030d3f830ba94b6e644850f4efd4443
First added on: May 11, 2024